Matinum

Taking Charge of Your Health


A key challenge with neurodegenerative
diseases is that they progress slowly so takes a long time for a clinician to use
standard tests to determine whether a patient has improved or not given some
form of treatment thanks to the generosity of the Duchenne Research Fund
we are now able to try to apply this technology to help children who suffer
from Duchenne muscular dystrophy in our lab we pioneered the combination of
artificial intelligence with wearable sensors to deliver technology that can
more rapidly detect the progression of diseases in a close collaboration with
the leading clinical scientists Professor Thomas Voit from Great Ormond
Street Hospital we’re going to study how we can deploy this AI in wearable
technology to assess and test whether we can more rapidly detect the progression
of Duchenne muscular dystrophy we’re conducting a 12 month long study where
children are going to wear sensors 24/7 so we can measure the movements and
their ability to interact with the world so the devices look basically like
smartwatches that you can wear on your arms on your wrist on your ankles and they
capture movements 24/7 this is basically like having your personal neurologist
looking at you in a clinical assessment every day every night and then deploy
artificial intelligence to make sense of these patterns and detect whether we can
see progression of a disease or not in using artificial intelligence we hope
that we can again as we’ve done in the past extract meaningful patterns that
are potentially very subtle so subtle that a human observer cannot pick
up but our algorithms can to determine if you’re improving or decreasing in
your health these technologies can then be used to help people who suffer from
rare diseases such as Duchenne muscular dystrophy our aims are twofold first we
want to replace subjective assessments carried out by humans observing somebody
else with objective artificial intelligence markers in second using
these markers we hope to be able to reduce the amount of time it takes to
detect disease progression if we can reduce this amount of time by
half we would effectively cut in half the cost of clinical trials for any
pharmaceuticals developed to address the specific disease we hope that this AI
for healthcare technology will not only work for Duchenne muscular dystrophy but
could also be used for many other rare and neglected diseases where currently
pharmaceutical development is not viable because the cost of clinical
trials

Leave a Reply

Your email address will not be published. Required fields are marked *